CMR Findings in COVID-19 Patients Presenting With Myocardial Infarction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-01

Study Completion Date

2023-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare myocardial injury in COVID 19 patients presented with myocardial infarction and non COVID Patients presented with myocardial infarction evaluated with CMR

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Patterns of Arrhythmias and Conduction Block in COVID-19 Patients and Its Relation to Myocardial Injury Detected by Cardiac Magnetic Resonance

NCT04584411

Covid19

UNKNOWN

Role of CMR-FT in Assessment of HCM and Athlete's Heart.

NCT06859827

Hypertrophic Cardiomyopathies Athlete Heart

ACTIVE_NOT_RECRUITING

Prevalence of Myocardial Scars on CMR After COVID-19 Infection

NCT04636320

COVID-19 Virus Disease

COMPLETED NA

Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance (R-COVID-CMR)

NCT04864899

Covid19 Viral Respiratory Infection

COMPLETED NA

CMR in Patients With Myocarditis

NCT01962584

Suspected Acute Myocarditis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Coronavirus disease 2019 (COVID-19) is a global pandemic affecting 185 countries and \>3 000 000 patients worldwide as of April 28, 2020. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2,. Among patients with COVID-19, there is a high prevalence of cardiovascular disease, and \>7% of patients experience myocardial injury from the infection (22% of critically ill patients). Although angiotensin-converting enzyme 2 serves as the portal for infection, the role of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers requires further investigation.

However, much like any other respiratory tract infection, pre-existing cardiovascular disease (CVD) and CV risk factors enhance vulnerability to COVID-19. Further, COVID-19 can worsen underly- ing CVD and even precipitate de novo cardiac complications.

Preliminary reports suggest that haemostatic abnormalities, including disseminated intravascular coagulation (DIC), occur in patients affected by COVID-19. Additionally, the severe inflammatory response, critical illness, and underlying traditional risk factors may all predispose to thrombotic events, similar to prior virulent zoonotic coronavirus outbreaks CMR is the reference non-invasive standard for cardiac function and tissue characterization and may offer an effective and efficient diagnostic imaging choice to obtain critical information for clinical decision-making.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COVID-19 patients presented with myocardial infarction

cardiac magnetic resonance

Intervention Type RADIATION

o CMR protocol:

* Cine imaging to assess regional \& global ventricular function according to the AHA 16-segment model.
* T2-weighted imaging to detect extent \& distribution of myocardial edema.
* Early Gd enhancement imaging to detect extent \& distribution of myocardial hyperemia.
* Late Gd enhancement imaging to detect extent \& distribution of myocardial necrosis.
* Single-short sequences \& other acceleration techniques will be used as appropriate in patients with poor ability to hold their breath.
* Post-processing analysis will be done on a dedicated workstation

Non-COVID-19 patients presented with myocardial infarction

cardiac magnetic resonance

Intervention Type RADIATION

o CMR protocol:

* Cine imaging to assess regional \& global ventricular function according to the AHA 16-segment model.
* T2-weighted imaging to detect extent \& distribution of myocardial edema.
* Early Gd enhancement imaging to detect extent \& distribution of myocardial hyperemia.
* Late Gd enhancement imaging to detect extent \& distribution of myocardial necrosis.
* Single-short sequences \& other acceleration techniques will be used as appropriate in patients with poor ability to hold their breath.
* Post-processing analysis will be done on a dedicated workstation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cardiac magnetic resonance

o CMR protocol:

* Cine imaging to assess regional \& global ventricular function according to the AHA 16-segment model.
* T2-weighted imaging to detect extent \& distribution of myocardial edema.
* Early Gd enhancement imaging to detect extent \& distribution of myocardial hyperemia.
* Late Gd enhancement imaging to detect extent \& distribution of myocardial necrosis.
* Single-short sequences \& other acceleration techniques will be used as appropriate in patients with poor ability to hold their breath.
* Post-processing analysis will be done on a dedicated workstation

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients presenting with symptoms and ECG indicative of acute MI (both STEMI \& NSTEMI) AND confirmed COVID-19.
2. Patients admitted with acute MI (both STEMI \& NSTEMI) who develop COVID-19 symptoms during hospital admission \& are confirmed by RT-PCR to have COVID-19

Exclusion Criteria

1. History of previous diagnosis of STEMI or myocarditis.
2. History of previous PCI in infarcted related artery or NSTEMI
3. Severe respiratory distress that precludes lying supine in the CMR scanner.
4. Acute kidney injury with rapidly declining GFR or GFR that is persistently below 30 ml/min/1.73 m2 (contraindication for Gadopentetate dimeglumine contrast).

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No